scholarship

Lysogene Proclaims Up to date Knowledge and Key Outcomes from the AAVance Section 2/3 Gene Remedy Medical Trial on Wednesday, November 23, 2022

  • Live webcast scheduled for Wednesday 23 November 2022 at 13:30 CET

PARIS–(BUSINESS WIRE)–Regulatory News:

Lysogene (FR0013233475 – LYS), a phase 3 biopharmaceutical company based on a gene therapy technology platform targeting central nervous system (CNS) disorders, today announced that on Wednesday, November 23, 2022 at 1:00 p.m. 30:00 GMT, a live webcast presenting updated data and key results from AAVance’s Phase 2/3 gene therapy clinical trial evaluating LYS-SAF302, an investigational gene therapy for the treatment of MPS IIIA.

Attendees can register for the webcast using the following link https://channel.royalcast.com/landingpage/lysogene/20221123_1/. Participants are advised to register in advance. Webcast information will also be available at www.lysogene.com/events.

About lysogen

Lysogene is a biopharmaceutical company focused on gene therapies for diseases of the central nervous system (CNS). The company has developed a unique capability that enables it to deliver CNS gene therapies to treat lysosomal storage diseases and other CNS genetic disorders. Lysogene is currently conducting a phase 2/3 clinical trial in MPS IIIA. An adaptive clinical trial of GM1 gangliosidosis is ongoing. Lysogene is also developing an innovative AAV gene therapy approach to treat Fragile X Syndrome, a genetic disorder associated with autism. The Company has also signed an exclusive worldwide license agreement with Yeda, the commercial entity of the Weizmann Institute of Science, for a gene therapy drug candidate to treat Parkinson’s disease associated with mutations in the GBA1 gene. www.lysogene.com.

Lysogenic Forward-Looking Statements

This press release may contain forward-looking statements, including the progress of clinical trials and the Company’s cash flow projection. Although the Company believes that its projections are based on reasonable assumptions, any statements, other than statements of historical fact, that this press release may contain regarding future events are subject to (i) change without notice, (ii) factors affecting beyond the Company’s control, (iii) results of clinical trials, (iv) increases in manufacturing costs, (v) potential claims on its products. These statements may include, without this list being exhaustive, any statements beginning with words or phrases such as “goal”, “believe”, “plan”, “aim”, “intend”, “may”, “anticipate”, ” estimate”, “plan”, “forecast”, “should”, “may have”, “probably”, “should”, “could” and other words and phrases with the same meaning or associate in the negative. Forward-looking statements are subject to inherent risks and uncertainties that are beyond the Company’s control, which may cause the Company’s actual results, performance or achievements to differ materially from those anticipated or expressed or implied by such forward-looking statements. A list and description of these risks, uncertainties and uncertainties appear in the Company’s filings with the Autorité des Marchés Financiers (AMF) in relation to its regulatory obligations, including the Company’s 2021 Universal Registration Document, which is registering with the is AMF on April 19, 2022 and in the documents and reports subsequently published by the Company. In addition, these forward-looking statements speak only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company undertakes no obligation to publicly update these forward-looking statements or to update the reasons why actual results may differ materially from those anticipated in the forward-looking statements, even if they do is new information would become available. The Company’s updating of one or more forward-looking statements does not imply that it will or will not update such forward-looking statements or any other forward-looking statements.

contacts

Como from La Tour du Pin

Deputy Administrative and Financial Director

[email protected]
+ 33 1 41 43 03 90

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button